1. Home
  2. CCLD vs ENGN Comparison

CCLD vs ENGN Comparison

Compare CCLD & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CareCloud Inc.

CCLD

CareCloud Inc.

HOLD

Current Price

$2.44

Market Cap

98.6M

Sector

Technology

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.79

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCLD
ENGN
Founded
1999
1999
Country
United States
Canada
Employees
3650
82
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
98.6M
117.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CCLD
ENGN
Price
$2.44
$1.79
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$21.08
AVG Volume (30 Days)
190.5K
936.9K
Earning Date
05-07-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.49
N/A
Revenue Next Year
$7.95
N/A
P/E Ratio
$32.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.04
$1.40
52 Week High
$4.01
$12.25

Technical Indicators

Market Signals
Indicator
CCLD
ENGN
Relative Strength Index (RSI) 58.71 39.26
Support Level $2.18 $1.68
Resistance Level $2.42 $1.85
Average True Range (ATR) 0.08 0.10
MACD 0.02 0.01
Stochastic Oscillator 80.95 10.00

Price Performance

Historical Comparison
CCLD
ENGN

About CCLD CareCloud Inc.

CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: